# Allogene Therapeutics Inc. (ALLO)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $393M  
**Price:** $1.78 (-2.20%)

> Allogene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing investigational allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer and autoimmune diseases. These 'off-the-shelf' products aim to provide faster, more reliable, and scalable cell therapy options compared to autologous approaches, leveraging healthy donor T cells engineered with multiplex gene-editing and proprietary lymphodepletion technologies. Key programs include cemacabtagene ansegedleucel (cema-cel) for frontline large B-cell lymphoma, ALLO-316 targeting clear cell renal cell carcinoma, and ALLO-329 for autoimmune conditions, with ongoing pivotal Phase 2 trials like ALPHA3 and RESOLUTION. Allogene Therapeutics Inc. maintains state-of-the-art in-house manufacturing and collaborates with partners such as Cellectis, Servier, and Arbor Biotechnologies to advance its pipeline. Headquartered in South San Francisco, California, the company operates a fully integrated platform from discovery through development, positioning it as a leader in redefining cell therapy accessibility for blood cancers, solid tumors, and autoimmune disorders.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | — | — | -$209M | -$191M | — |
| 2024 | $22,000 | — | -$273M | -$258M | — |
| 2023 | $95,000 | — | -$328M | -$327M | — |
| 2022 | $156,000 | — | -$336M | -$340M | — |
| 2021 | $114M | — | -$180M | -$182M | — |
| 2020 | — | — | -$258M | -$316M | — |
| 2019 | — | — | -$202M | -$185M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $416M | $123M | $293M | $52M | — |
| 2024 | $549M | $127M | $422M | $75M | — |
| 2023 | $643M | $131M | $512M | $83M | — |
| 2022 | $822M | $155M | $667M | $62M | — |
| 2021 | $1.05B | $126M | $925M | $173M | — |
| 2020 | $1.23B | $148M | $1.01B | $183M | — |
| 2019 | $718M | $89M | $629M | $175M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$149M | $386,000 | -$150M |
| 2024 | -$200M | $694,000 | -$201M |
| 2023 | -$238M | $2M | -$239M |
| 2022 | -$221M | $5M | -$226M |
| 2021 | -$185M | $21M | -$206M |
| 2020 | -$115M | $66M | -$181M |
| 2019 | -$137M | $51M | -$188M |
| 2018 | -$45M | $3M | -$48M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ALLO)